viewHarvest One Cannabis Inc.

Harvest One expands Satipharms proprietary Gelpell product offerings

New advanced range has two variants, Focus and Active, loaded with vitamins to support body health and movement, and mental wellbeing

Harvest One Cannabis Inc. - Harvest One expands Satipharms proprietary Gelpell product offerings
Manufactured in Switzerland and GMP-certified, every Gelpell capsule delivers a consistent dose of cannabinoids, according to the company

Harvest One Cannabis Inc (CVE:HVT) (OTCQX:HRVOF) said Wednesday that its wholly-owned subsidiary Satipharm Ltd has expanded its product offerings to include two new variants of its unique proprietary CBD Gelpell product, further enhancing its product portfolio currently on sale in major retailers and pharmacy chains throughout the United Kingdom and Ireland.

In a statement, the Vancouver-based company said the new Satipharm CBD advanced range products combine CBD with specifically selected vitamins in the company's proprietary Gelpell capsules. The patented Gelpell technology delivers CBD in “seamless microbeads that are clinically proven to increase bioavailability,” noted the company.

READ: Harvest One Cannabis appoints Andy Bayfield as interim CEO

The new advanced range offers two variants, Focus and Active, designed to address specific consumer's needs:

  • Active: Satipharm CBD Advanced Active combines CBD with vitamins A, D, E and K to support general body health and movement
  • Focus: Satipharm CBD Advanced Focus combines CBD with B vitamins to support mental wellbeing

Harvest One Cannabis CEO Andy Bayfield pointed out that “a differentiated product offering” is key to building a successful brand, as the company continues to expand its distribution with retailers and pharmacy chains in the United Kingdom and Ireland.

"These innovative new product variations, Active and Focus offer our consumers solutions to specific needs, while leveraging our proven Gelpell delivery technology," Bayfield said.

Satipharm's suite of products now includes its flagship product - a 10 mg CBD Gelpell capsule, a high-strength 50 mg CBD Gelpell capsule and the CBD advanced range Focus and Active variants. It also includes Satipharm's range of Lemon & Lime and Cinnamon flavoured CBD oils providing a differentiated market offering to satisfy a larger consumer base.

Manufactured in Switzerland and GMP-certified, every Gelpell capsule delivers a “consistent dose of cannabinoids,” the company noted, while also pointing out that Satipharm CBD Gelpell capsules have “3.5 times higher bioavailability compared to standard CBD oils.”

The capsules have undergone Stage I and Stage II clinical trials with the results published in two peer-reviewed international medical journals.

Harvest One serves as an umbrella over three wholly-owned subsidiaries: United Greeneries, which is a licensed cannabis producer; Satipharm, which develops cannabis-based health products; and Dream Water, which offers consumer sleep aids.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Quick facts: Harvest One Cannabis Inc.

Price: 0.06 CAD

Market: TSX-V
Market Cap: $12.9 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Harvest One Cannabis Inc. named herein, including the promotion by the Company of Harvest One Cannabis Inc. in any Content on the Site, the...


Full interview: Harvest One Cannabis receives Health Canada cultivation...

Harvest One Cannabis Inc (CVE:HVT) (OTCMKTS:HRVOF) Senior Vice President of Corporate & Public Affairs Will Stewart tells Proactive the cannabis company has earned a cannabis cultivation license from Health Canada for phase one of its Mission Road facility in Duncan, British...

on 10/15/2019

2 min read